Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, darunavir (Prezista®) cannot be endorsed for use within NHS Wales co-administered with cobicistat in combination with other antiretroviral (ART) medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients. |
||
|
||
Medicine details |
||
| Medicine name | darunavir (Prezista®) | |
| Formulation | 100 mg and 800 mg film-coated tablet and 100 mg/ml oral suspension | |
| Reference number | 2580 | |
| Indication | Co-administered with cobicistat in combination with other antiretroviral (ART) medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients |
|
| Company | Janssen-Cilag Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 10/03/2015 | |